All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Assoc. Prof. Tapan Kadia | ASH 2017 | New novel agents in AML
Assoc. Prof. Tapan Kadia | ASH 2017 | New novel agents in AML 59th ASH annual ASH Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
ASH 2017 | IDH inhibitors in mIDH1 and mIDH2 AML – Enasidenib monotherapy in previously untreated IDH2 mutated AML and Ivosidenib and enasidenib in combination with azacitidine in newly diagnosed IDH mutated AML
At the 59th American Society of...
Subscribe to get the best content related to AML delivered to your inbox